Sort
21,453 grants matching “tuberculosis”
[R21] Integrated computer-aided, point-of-care ultrasound for tuberculosis screening
$223,064Yingda Linda Xie · Rbhs-New Jersey Medical School · R21 · FY2022 · AI
Therapeutic Restoration of Metabolic Homeostasis During Active TB
$223,050Randall J Basaraba · Colorado State University · R21 · FY2014 · AI
Environmental mycobacteria and BCG interference
$223,050Ian M Orme · Colorado State University · R21 · FY2015 · AI
Novel preclinical efficacy models against nontuberculosis mycobacteria
$223,050Diane Joyce Ordway · Colorado State University · R21 · FY2014 · AI
BCG efficacy against W-Beijing TB strains
$223,050Ian M Orme · Colorado State University · R21 · FY2015 · AI
Innovative Approaches for TB Control in Brazil
$223,033Jonathan E Golub · Johns Hopkins University · U2R · FY2014 · TW
Tulane Xavier Minority Training in International Health
$223,030Richard A Oberhelman · Tulane University Of Louisiana · T37 · FY2016 · MD
CD1-RESTRICTED T CELLS AGAINST THE TULAREMIA PATHOGEN
$223,013University Of California Los Angeles · R21 · FY2005 · AI
Translational Science
$222,950Christine A Wanke · Miriam Hospital · P30 · FY2007 · AI
UCSF-UCB TRAC ADMININSTRATIVE CORE
$222,903Payam Nahid · University Of California, San Francisco · P30 · FY2025 · AI
Oral Pathogens and Dendritic Cell Subsets
$222,879Christopher W Cutler · State University New York Stony Brook · R01 · FY2011 · DE
Non-tuberculous Mycobacteria & Heterologous Immunity
$222,775Thomas R Hawn · University Of Washington · R21 · FY2019 · AI
Rapid characterization of mycobacteria and drug resistance in paucibacillary TB
$222,750Blanca I Restrepo · University Of Texas Hlth Sci Ctr Houston · R21 · FY2006 · AI
The role of Chlamydia trachomatis specific HLA-E restricted CD8 T cell responses in clearance of infection
$222,750Anju Bansal · University Of Alabama At Birmingham · R21 · FY2023 · AI
Control of latent/persistent HIV-1 infection in macrophages/microglia: A key role for the phosphatase PPM1A
$222,750Olaf Kutsch · University Of Alabama At Birmingham · R21 · FY2021 · DA
Virulence of MDR-TB strains
$222,750Ian M Orme · Colorado State University · R21 · FY2013 · AI
A Novel Approach for Mycobacterium Tuberculosis Vaccine Development
$222,750Biao He · University Of Georgia · R21 · FY2014 · AI
The splicing factor SF3b1 is a master regulator of the innate immune response to Mycobacterium tuberculosis
$222,750Robert Owen Watson · Texas A&M University Health Science Ctr · R21 · FY2016 · AI
A Novel Proteomic Approach to TB Biomarker Discovery using Human Exosomes
$222,750John Lucian Davis · University Of California, San Francisco · R21 · FY2012 · AI
Novel membrane remodeling systems in Actinobacteria and their role in antibiotic resistance
$222,738Herve Roy · University Of Central Florida · R21 · FY2019 · AI
PHASE 1 CLINICAL TRIALS UNITS FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES: EVALUATION OF THERAPEUTICS FOR TUBERCULOSIS
$222,661David Shumway · Dynport Vaccine Company, Llc · N01 · FY2017 · AI
Infectious Diseases Training program in Bolivia: South-South Training with Peru
$222,659Robert H Gilman · Johns Hopkins University · D43 · FY2015 · TW
Nanoparticle delivery system for antiturberculosis drug
$222,615National Jewish Health · R21 · FY2003 · AI
Role of gamma/delta T cells in Vaccine Induced Immunity
$222,535Daniel F. Hoft · Saint Louis University · R01 · FY2015 · AI
Combining Xpert and GIS to identify areas of high tuberculosis transmission
$222,424Lesley Scott · Wits Health Consortium (Pty), Ltd · R21 · FY2015 · AI